Cargando…
The Prevalent Comorbidome at the Onset of Psoriasis Diagnosis
INTRODUCTION: Psoriasis (PsO) is currently regarded as a systemic inflammatory disease with a growing burden of post-diagnosis associated comorbidities. To determine the initial burden of comorbiditis we evaluated the comorbidome at PsO onset. METHODS: In a matched case–control study, we extracted d...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10442308/ https://www.ncbi.nlm.nih.gov/pubmed/37542678 http://dx.doi.org/10.1007/s13555-023-00986-0 |
_version_ | 1785093564667002880 |
---|---|
author | Buja, Alessandra Miatton, Andrea Cozzolino, Claudia Brazzale, Alessandra Rosalba Lo Bue, Roberta Mercuri, Santo Raffaele Proft, Fabian Nikolai Kridin, Khalaf Cohen, Arnon Dov Damiani, Giovanni |
author_facet | Buja, Alessandra Miatton, Andrea Cozzolino, Claudia Brazzale, Alessandra Rosalba Lo Bue, Roberta Mercuri, Santo Raffaele Proft, Fabian Nikolai Kridin, Khalaf Cohen, Arnon Dov Damiani, Giovanni |
author_sort | Buja, Alessandra |
collection | PubMed |
description | INTRODUCTION: Psoriasis (PsO) is currently regarded as a systemic inflammatory disease with a growing burden of post-diagnosis associated comorbidities. To determine the initial burden of comorbiditis we evaluated the comorbidome at PsO onset. METHODS: In a matched case–control study, we extracted data on 57,228 patients and 125 morbidities from the Clalit Health Services Israeli insurance database. PsO cases were matched with control individuals by sex and age at enrolment. As pre-existing comorbidities, we considered all conditions already present in controls at the same age as the matched PsO case at the time of their diagnosis. To test for differences in the odds of comorbidities between the case and control groups, logistic regression analyses were run to calculate the odds ratio (OR) for each comorbidity, after which the comorbidome was graphically represented. RESULTS: In this study we enrolled 28,614 PsO patients and 28,614 controls with an average age of 45.3 ± 19.6 years. At the time of diagnosis, PsO patients were more likely to be diagnosed with 2–4 comorbidities (28.8% vs 23.8%) and > 5 (19.6% vs 12.9%,). PsO patients’ specific comorbidomes evidenced several pathological cores: autoimmune and inflammatory systemic diseases [i.e., hidradenitis suppurativa (OR 3.55, 95% CI 1.88–7.28) or polymyalgia rheumatica (OR 3.01 95% CI 1.96–4.77)], inflammatory bowel diseases [i.e., Crohn’s disease (OR 2.99 95% CI 2.20–4.13)], pulmonary inflammatory diseases [i.e., chronic obstructive pulmonary disease (OR 1.81 95% CI 1.61–2.04)], hepatological diseases [i.e., cirrhosis (OR 2.00 95% CI 1.36–3.00)], endocrine diseases [dysthyroidisms (OR 1.82 95% CI 1.30–2.59)], mental disorders [i.e., depression (OR 1.72 95% CI 1.57–1.87)], and cardiovascular diseases (i.e., hypertension (OR 1.47 95% CI 1.41–1.53)]. CONCLUSION: The PsO-onset comorbidome may help health professionals plan more comprehensive patient management. By screening for these common PsO-linked conditions, early diagnosis and treatment may become more frequent, thus greatly benefiting patients on their medical journey. |
format | Online Article Text |
id | pubmed-10442308 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Springer Healthcare |
record_format | MEDLINE/PubMed |
spelling | pubmed-104423082023-08-23 The Prevalent Comorbidome at the Onset of Psoriasis Diagnosis Buja, Alessandra Miatton, Andrea Cozzolino, Claudia Brazzale, Alessandra Rosalba Lo Bue, Roberta Mercuri, Santo Raffaele Proft, Fabian Nikolai Kridin, Khalaf Cohen, Arnon Dov Damiani, Giovanni Dermatol Ther (Heidelb) Original Research INTRODUCTION: Psoriasis (PsO) is currently regarded as a systemic inflammatory disease with a growing burden of post-diagnosis associated comorbidities. To determine the initial burden of comorbiditis we evaluated the comorbidome at PsO onset. METHODS: In a matched case–control study, we extracted data on 57,228 patients and 125 morbidities from the Clalit Health Services Israeli insurance database. PsO cases were matched with control individuals by sex and age at enrolment. As pre-existing comorbidities, we considered all conditions already present in controls at the same age as the matched PsO case at the time of their diagnosis. To test for differences in the odds of comorbidities between the case and control groups, logistic regression analyses were run to calculate the odds ratio (OR) for each comorbidity, after which the comorbidome was graphically represented. RESULTS: In this study we enrolled 28,614 PsO patients and 28,614 controls with an average age of 45.3 ± 19.6 years. At the time of diagnosis, PsO patients were more likely to be diagnosed with 2–4 comorbidities (28.8% vs 23.8%) and > 5 (19.6% vs 12.9%,). PsO patients’ specific comorbidomes evidenced several pathological cores: autoimmune and inflammatory systemic diseases [i.e., hidradenitis suppurativa (OR 3.55, 95% CI 1.88–7.28) or polymyalgia rheumatica (OR 3.01 95% CI 1.96–4.77)], inflammatory bowel diseases [i.e., Crohn’s disease (OR 2.99 95% CI 2.20–4.13)], pulmonary inflammatory diseases [i.e., chronic obstructive pulmonary disease (OR 1.81 95% CI 1.61–2.04)], hepatological diseases [i.e., cirrhosis (OR 2.00 95% CI 1.36–3.00)], endocrine diseases [dysthyroidisms (OR 1.82 95% CI 1.30–2.59)], mental disorders [i.e., depression (OR 1.72 95% CI 1.57–1.87)], and cardiovascular diseases (i.e., hypertension (OR 1.47 95% CI 1.41–1.53)]. CONCLUSION: The PsO-onset comorbidome may help health professionals plan more comprehensive patient management. By screening for these common PsO-linked conditions, early diagnosis and treatment may become more frequent, thus greatly benefiting patients on their medical journey. Springer Healthcare 2023-08-05 /pmc/articles/PMC10442308/ /pubmed/37542678 http://dx.doi.org/10.1007/s13555-023-00986-0 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by-nc/4.0/Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Original Research Buja, Alessandra Miatton, Andrea Cozzolino, Claudia Brazzale, Alessandra Rosalba Lo Bue, Roberta Mercuri, Santo Raffaele Proft, Fabian Nikolai Kridin, Khalaf Cohen, Arnon Dov Damiani, Giovanni The Prevalent Comorbidome at the Onset of Psoriasis Diagnosis |
title | The Prevalent Comorbidome at the Onset of Psoriasis Diagnosis |
title_full | The Prevalent Comorbidome at the Onset of Psoriasis Diagnosis |
title_fullStr | The Prevalent Comorbidome at the Onset of Psoriasis Diagnosis |
title_full_unstemmed | The Prevalent Comorbidome at the Onset of Psoriasis Diagnosis |
title_short | The Prevalent Comorbidome at the Onset of Psoriasis Diagnosis |
title_sort | prevalent comorbidome at the onset of psoriasis diagnosis |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10442308/ https://www.ncbi.nlm.nih.gov/pubmed/37542678 http://dx.doi.org/10.1007/s13555-023-00986-0 |
work_keys_str_mv | AT bujaalessandra theprevalentcomorbidomeattheonsetofpsoriasisdiagnosis AT miattonandrea theprevalentcomorbidomeattheonsetofpsoriasisdiagnosis AT cozzolinoclaudia theprevalentcomorbidomeattheonsetofpsoriasisdiagnosis AT brazzalealessandrarosalba theprevalentcomorbidomeattheonsetofpsoriasisdiagnosis AT lobueroberta theprevalentcomorbidomeattheonsetofpsoriasisdiagnosis AT mercurisantoraffaele theprevalentcomorbidomeattheonsetofpsoriasisdiagnosis AT proftfabiannikolai theprevalentcomorbidomeattheonsetofpsoriasisdiagnosis AT kridinkhalaf theprevalentcomorbidomeattheonsetofpsoriasisdiagnosis AT cohenarnondov theprevalentcomorbidomeattheonsetofpsoriasisdiagnosis AT damianigiovanni theprevalentcomorbidomeattheonsetofpsoriasisdiagnosis AT bujaalessandra prevalentcomorbidomeattheonsetofpsoriasisdiagnosis AT miattonandrea prevalentcomorbidomeattheonsetofpsoriasisdiagnosis AT cozzolinoclaudia prevalentcomorbidomeattheonsetofpsoriasisdiagnosis AT brazzalealessandrarosalba prevalentcomorbidomeattheonsetofpsoriasisdiagnosis AT lobueroberta prevalentcomorbidomeattheonsetofpsoriasisdiagnosis AT mercurisantoraffaele prevalentcomorbidomeattheonsetofpsoriasisdiagnosis AT proftfabiannikolai prevalentcomorbidomeattheonsetofpsoriasisdiagnosis AT kridinkhalaf prevalentcomorbidomeattheonsetofpsoriasisdiagnosis AT cohenarnondov prevalentcomorbidomeattheonsetofpsoriasisdiagnosis AT damianigiovanni prevalentcomorbidomeattheonsetofpsoriasisdiagnosis |